Inotrem is a biotechnology company specializing in the development of new treatments for patients suffering from severe acute inflammatory diseases, such as septic shock. The company's approach is based on modulating the TREM-1 pathway, which is involved in the immune response.

Inotrem

Created over 20 years ago, Andera Partners is a major player in private company investments in France and internationally. Its teams manage over €3.6 billion in investments in life sciences (Andera Life Sciences), growth and buyout capital (Andera MidCap, Andera Expansion, Andera Croissance, Andera Co-Invest), sponsorless transactions (Andera Acto) and ecological transition (Andera Infra).Andera Partners’ mission is to work alongside companies and their managers to support them in achieving strong and sustainable growth. The quality of performance offered to our investors relies on a strong partnership between the entrepreneurs in our portfolio companies and our teams, based on shared values. Performance through collective engagement, the “Power of And”, constitutes Andera Partners’ DNA. Based in Paris, with offices in Antwerp and Munich, Andera Partners is wholly owned by its teams, which count nearly 95 professionals, of which 58 investment professionals. It is structured as a partnership and managed by a board of 10 partners. Responsible and committed, the management company regularly forms partnerships with non-profit sector entities and takes concrete action in the fight against global warming. Andera Partners has been certified carbon neutral since 2018.  

Verona Pharma

Cellectis

Lhyfe

LogicBio Therapeutics

Amolyt Pharma

Arvelle Therapeutics

Axonics Modulation Technologies

Intech

Corvidia

erytech

ReViral

SANIFIT

TME Pharma

Poxel

Vivoryon Therapeutics

Cormorant Asset Management

Andera Partners

Squarepoint Capital

Taglich Brothers

Richmond Brothers, Inc.

COM:ANDERAPARTNERS

Inotrem

Financials Not Available